论文部分内容阅读
目的 :探讨氯化锶 (89SrCl2 )治疗泌尿外科肿瘤骨转移的临床应用价值。方法 :1996年 6月～ 2 0 0 1年 6月应用89SrCl2 (0 .0 14 8× 10 10 Bq/次 )静脉注射治疗前列腺癌、膀胱癌及肾癌骨转移8例。随访 1年 1个月～ 4年 11个月。结果 :8例患者疼痛缓解 ,其中 2例前列腺癌骨转移病灶消失 ,1例大部分吸收 ,1例膀胱癌因全身多器官转移用药 4个月后死亡 ,1例前列腺癌用药 3个月后死于心脏病。结论 :89SrCl2 治疗泌尿系肿瘤所引起的骨转移既能缓解疼痛 ,亦可使部分病灶得到缩小 ,使大多数患者生活质量得以改善 ,病情缓解 ,寿命延长。
Objective: To investigate the clinical value of strontium chloride (89SrCl2) in the treatment of bone metastases from urological tumors. Methods: Eight cases of bone metastases from prostate cancer, bladder cancer and kidney cancer were treated with 89SrCl2 (0.0148 × 10 10 Bq / time) from June 1996 to June 2001. Follow-up 1 year 1 month ~ 4 years and 11 months. Results: Pain was relieved in 8 patients, 2 cases of bone metastases disappeared in prostate cancer, 1 case was mostly absorbed, 1 case of bladder cancer died after 4 months of systemic multi-organ metastasis and 1 case of prostate cancer died after 3 months In heart disease. Conclusion: 89SrCl2 treatment of urinary tumors caused by bone metastases can both relieve pain, but also can make some lesions reduced, so that most patients with improved quality of life, condition, life expectancy.